Sangita M. Baxi

Photo of Sangita Baxi
Assistant Policy Researcher; Ph.D. Candidate, Pardee RAND Graduate School
Santa Monica Office

Education

M.A.S. in health policy & law, University of California - San Diego and California Western School of Law; B.S. in biology, University of Michigan - Ann Arbor

Overview

Sangita Baxi is an assistant policy analyst at RAND and a doctoral student at the Pardee RAND Graduate School. She has an M.A.S. in health policy and law from the University of California, San Diego, and the California Western School of Law, and a B.S. in biology from the University of Michigan, Ann Arbor.

Prior to joining Pardee RAND, Baxi was a research scientist in early-stage drug discovery for cardiovascular and oncology indications at Pfizer Inc. Her research interests include developing countries, international development, health care systems, health economics, social determinants of health, and science and technology policy.

Commentary

  • Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, in Seattle, Washington, March 31, 2020, photo by Lindsey Wasson/Reuters

    The Unintended Consequences of a Proposed Cure for COVID-19

    The very discussion of chloroquine and hydroxychloroquine as therapeutic options against COVID-19 has decreased their availability for proven treatments, exacerbated global shortages, fueled a rampant counterfeit drug market in Africa, and worsened trade tensions. What can be done to deal with these unintended consequences?

    Apr 29, 2020 The Hill

Publications